RAC 1.61% $1.83 race oncology ltd

Cardioprotection thread, page-467

  1. 2,718 Posts.
    lightbulb Created with Sketch. 3299
    We're currently only pursuing Zan + Anthracyclines in the clinic (although Sheba 2.0 might yet validate CPACS in liquid tumours). Upside on any opportunity outside this space would be heavily discounted without clinical validation.

    https://hotcopper.com.au/data/attachments/6135/6135630-071ede156debf2b44234d4432f9cc3a1.jpg

    Assume that CPACS w/ Anthracyclines is validated in all solid tumours in this coming P1a/b trial... If Zan was used in combination with 10% of the US Anthracycline market that could net $1.1B in peak annual sales (note the Triangle report forecasts greater CPACS peak revenue in m/NBC alone @ ~US$1.6B). My base case valuation scenario (if CPACS is clinically validated) for an Anthracycline synergy might be 4 x peak sales of US$1.1B (>AU$6B).

    Assume further dilution from here and RAC winds up with ~250m SOI. That's $24/share.

    You can scale market capture, include additional geographies and adjust dilution as you please.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.83
Change
-0.030(1.61%)
Mkt cap ! $311.7M
Open High Low Value Volume
$1.86 $1.91 $1.79 $169.3K 92.02K

Buyers (Bids)

No. Vol. Price($)
1 92 $1.83
 

Sellers (Offers)

Price($) Vol. No.
$1.87 3472 1
View Market Depth
Last trade - 16.10pm 19/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.